Tricore Reference Laboratories

Tricore Reference Laboratories was paid $64.46M by Medicaid between Jan 2018 and Dec 2022, across 342 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 12% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New Mexico

Rank by total paid#1 of 11

Median peer was paid$1.26M

This provider vs. median51×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	685,866	$13.02M
2019	702,664	$13.49M
2020	662,853	$15.34M
2021	795,491	$15.02M
2022	387,698	$7.59M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	12%	94,098	66,741	$7.80M
80050	General health panel	6.5%	88,950	88,085	$4.22M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	4.2%	77,812	76,032	$2.70M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	4.2%	77,805	76,025	$2.70M
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	3.9%	90,035	89,051	$2.50M
80061	Lipid panel	3.3%	169,021	167,107	$2.12M
80053	Comprehensive metabolic panel	3.0%	197,990	187,378	$1.93M
84443	Thyroid stimulating hormone (TSH)	2.7%	113,833	111,997	$1.75M
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	2.3%	3,697	3,616	$1.46M
83036	Hemoglobin; glycosylated (A1C)	2.0%	139,812	138,168	$1.27M
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.8%	50,877	50,138	$1.18M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	1.8%	11,131	10,323	$1.13M

330 more codes

88305	Level IV - Surgical pathology, gross and microscopic examination	1.7%	14,300	$1.10M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	1.7%	17,409	$1.10M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.5%	41,971	$987K
81420	Fetal chromosomal aneuploidy genomic sequence analysis panel	1.5%	1,414	$986K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.5%	138,491	$985K
87902		1.5%	3,728	$964K
80074		1.3%	18,846	$857K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	1.3%	32,048	$826K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.2%	16,143	$804K
84439		1.2%	93,204	$796K
81511		1.2%	4,732	$775K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	1.2%	22,144	$757K
81514		1.1%	3,512	$731K
87481		1.1%	7,202	$721K
86780		1.0%	49,248	$645K
87086	Culture, bacterial; quantitative colony count, urine	<1%	78,723	$612K
36415	Collection of venous blood by venipuncture	<1%	226,968	$605K
87522	Neg quan hep c or qual rna	<1%	14,196	$596K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	7,456	$523K
85027		<1%	79,822	$477K
86803		<1%	33,837	$459K
82607		<1%	32,164	$454K
82728		<1%	33,633	$429K
84403		<1%	16,737	$426K
88307		<1%	1,896	$409K
84481		<1%	25,222	$407K
86003		<1%	5,598	$361K
87505		<1%	3,040	$357K
87631		<1%	2,357	$308K
81508		<1%	2,980	$292K
82670		<1%	9,097	$289K
87653		<1%	8,247	$273K
83970		<1%	7,972	$269K
83550		<1%	32,672	$265K
88342		<1%	3,172	$263K
84153		<1%	15,482	$263K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	7,396	$260K
82746		<1%	18,515	$255K
87077		<1%	29,022	$253K
84270		<1%	11,713	$248K
87340		<1%	24,332	$240K
83540		<1%	35,825	$216K
86038		<1%	18,565	$212K
83001		<1%	11,931	$210K
84702		<1%	14,572	$209K
86480		<1%	3,656	$208K
87480		<1%	10,248	$203K
87510		<1%	10,238	$202K
87660		<1%	10,223	$201K
82570		<1%	40,974	$196K
86762		<1%	14,057	$195K
87186		<1%	22,041	$195K
88341		<1%	1,117	$195K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	3,806	$189K
86235		<1%	3,311	$188K
86376		<1%	13,171	$187K
80048	Basic metabolic panel (calcium, ionized)	<1%	22,980	$180K
87650		<1%	8,503	$176K
83520		<1%	2,326	$166K
82043		<1%	30,044	$160K
83516		<1%	7,620	$158K
83880		<1%	4,545	$149K
87632		<1%	655	$145K
86140		<1%	29,545	$143K
84146		<1%	7,420	$141K
84480		<1%	10,451	$141K
86147		<1%	1,941	$138K
87536		<1%	1,686	$137K
88312		<1%	1,234	$135K
86146		<1%	1,756	$123K
86850		<1%	14,426	$122K
82105		<1%	7,244	$116K
86706		<1%	10,538	$112K
83002		<1%	6,101	$108K
84144		<1%	5,459	$105K
88141		<1%	4,348	$104K
83735		<1%	15,511	$100K
81001		<1%	33,833	$100K
82274		<1%	5,711	$99K
86696		<1%	5,200	$97K
88304		<1%	3,002	$97K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	817	$95K
87338		<1%	6,520	$91K
80076		<1%	11,076	$86K
87529		<1%	1,840	$83K
85652		<1%	31,296	$79K
86431		<1%	14,735	$79K
86160		<1%	3,502	$79K
86787		<1%	6,002	$79K
83655		<1%	6,347	$79K
82731		<1%	1,212	$75K
84436		<1%	11,287	$74K
86704		<1%	6,217	$74K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	340	$69K
86694		<1%	1,784	$68K
86800		<1%	4,212	$67K
82784		<1%	6,453	$67K
86665		<1%	1,908	$67K
86695		<1%	5,208	$66K
86708		<1%	5,428	$66K
82533		<1%	2,369	$64K
85610		<1%	16,409	$63K
83690		<1%	9,226	$61K
86200		<1%	4,942	$60K
87081		<1%	8,909	$59K
88185		<1%	237	$57K
84207		<1%	1,151	$57K
84425		<1%	1,352	$56K
80069		<1%	7,301	$55K
84550		<1%	13,048	$54K
87581		<1%	1,696	$53K
87486		<1%	1,694	$53K
84445		<1%	849	$53K
82248		<1%	10,940	$52K
87070		<1%	6,187	$52K
83525		<1%	4,706	$51K
82671		<1%	1,343	$50K
85060		<1%	2,289	$49K
82627		<1%	2,370	$49K
86304		<1%	2,254	$43K
88360		<1%	235	$43K
84156		<1%	12,799	$42K
87075		<1%	4,463	$41K
85730		<1%	7,185	$41K
86900		<1%	14,423	$40K
86901		<1%	14,380	$40K
80164		<1%	2,715	$39K
82950		<1%	8,592	$39K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	467	$38K
82150		<1%	6,019	$38K
80197		<1%	3,031	$37K
86255		<1%	2,028	$36K
82785		<1%	2,306	$36K
84154		<1%	2,107	$35K
0225U		<1%	84	$35K
85390		<1%	1,072	$34K
83615		<1%	6,149	$34K
86225		<1%	2,603	$33K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	207	$33K
82626		<1%	604	$33K
81003		<1%	15,697	$33K
86769		<1%	842	$33K
88112		<1%	782	$32K
84630		<1%	857	$32K
82140		<1%	2,326	$30K
86039		<1%	2,869	$30K
G0452	Molecular pathology procedure; physician interpretation and report	<1%	1,707	$30K
82951		<1%	2,508	$30K
82977		<1%	3,920	$30K
84100		<1%	7,172	$29K
82247		<1%	5,967	$29K
83498		<1%	584	$27K
86141		<1%	2,281	$27K
88313		<1%	340	$27K
87205		<1%	6,438	$27K
81374		<1%	377	$26K
82378		<1%	1,495	$25K
82024		<1%	678	$24K
82550		<1%	3,836	$24K
82397		<1%	1,791	$23K
82525		<1%	583	$23K
84460		<1%	4,494	$22K
84165		<1%	2,425	$22K
84450		<1%	4,459	$22K
82565		<1%	4,539	$21K
84681		<1%	1,022	$20K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	262	$19K
80178		<1%	3,061	$19K
83090		<1%	1,155	$18K
84432		<1%	716	$17K
84163		<1%	206	$17K
85613		<1%	1,907	$17K
86765		<1%	1,254	$17K
84484		<1%	932	$16K
86735		<1%	1,152	$16K
83020		<1%	1,133	$16K
87328		<1%	1,213	$15K
86361		<1%	593	$15K
87329		<1%	1,231	$15K
83921		<1%	816	$15K
88142		<1%	729	$15K
82040		<1%	3,164	$15K
86632		<1%	243	$14K
87449		<1%	1,106	$13K
86631		<1%	243	$13K
86664		<1%	859	$13K
88173		<1%	111	$13K
86256		<1%	853	$12K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	84	$12K
82652		<1%	258	$12K
80177		<1%	1,002	$12K
88184		<1%	249	$12K
88302		<1%	405	$12K
86593		<1%	2,835	$12K
86644		<1%	668	$12K
86334		<1%	658	$12K
85379		<1%	1,213	$11K
86663		<1%	859	$11K
82390		<1%	1,093	$11K
84134		<1%	768	$10K
86060		<1%	1,409	$10K
83993		<1%	556	$10K
87324		<1%	831	$10K
88189		<1%	173	$9K
86689		<1%	357	$9K
87088		<1%	1,111	$9K
81025		<1%	1,119	$9K
81408		<1%	12	$9K
86645		<1%	488	$8K
86618		<1%	212	$8K
83789		<1%	42	$8K
84305		<1%	317	$7K
80156		<1%	484	$7K
87799		<1%	188	$7K
85018		<1%	3,135	$7K
86258		<1%	667	$7K
85046		<1%	1,318	$7K
88311		<1%	522	$6K
G0475	Hiv antigen/antibody, combination assay, screening	<1%	472	$6K
82952		<1%	1,696	$6K
82085		<1%	274	$6K
86705		<1%	541	$6K
84482		<1%	135	$6K
86364		<1%	652	$6K
81513		<1%	61	$6K
84478		<1%	1,025	$6K
87147		<1%	616	$6K
83521		<1%	247	$6K
84466		<1%	432	$5K
86300		<1%	262	$5K
82947		<1%	1,375	$5K
84520		<1%	1,183	$5K
86341		<1%	50	$5K
82575		<1%	571	$5K
85014		<1%	2,135	$5K
82310		<1%	955	$5K
84155		<1%	1,435	$4K
80185		<1%	376	$4K
86777		<1%	298	$4K
87102		<1%	538	$4K
86008		<1%	12	$4K
84166		<1%	276	$4K
81404		<1%	20	$4K
86308		<1%	716	$4K
82103		<1%	222	$4K
82330		<1%	303	$4K
84132		<1%	750	$3K
83519		<1%	28	$3K
87209		<1%	178	$3K
U0001	Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel	<1%	86	$3K
84300		<1%	689	$3K
81161		<1%	25	$3K
80175		<1%	232	$3K
84479		<1%	428	$3K
88365		<1%	30	$3K
86778		<1%	153	$3K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	86	$3K
82610		<1%	52	$3K
88331		<1%	29	$2K
83825		<1%	104	$2K
85045		<1%	622	$2K
85306		<1%	157	$2K
81241		<1%	39	$2K
82239		<1%	54	$2K
80165		<1%	72	$2K
81406		<1%	13	$2K
82175		<1%	78	$2K
85303		<1%	151	$2K
85300		<1%	165	$2K
86870		<1%	128	$2K
86381		<1%	69	$2K
86709		<1%	138	$2K
82668		<1%	87	$2K
87177		<1%	178	$2K
86036		<1%	141	$1K
81243		<1%	48	$1K
80348		<1%	61	$1K
81400		<1%	31	$1K
88291		<1%	41	$1K
87206		<1%	199	$1K
86747		<1%	12	$915.60
81222		<1%	79	$870.14
86015		<1%	89	$808.06
86738		<1%	26	$756.78
86635		<1%	12	$746.03
81270		<1%	12	$678.06
85246		<1%	28	$677.03
82164		<1%	25	$655.70
87040		<1%	54	$633.59
82553		<1%	63	$614.66
83883		<1%	25	$606.93
82985		<1%	27	$585.28
G0145	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	<1%	22	$581.70
85245		<1%	25	$581.37
81257		<1%	12	$569.05
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	42	$553.41
83721		<1%	61	$534.99
85240		<1%	28	$526.63
82679		<1%	12	$513.91
84590		<1%	16	$467.36
87517		<1%	14	$456.61
85384		<1%	50	$428.53
86880		<1%	39	$372.56
88300		<1%	31	$353.95
80361		<1%	179	$335.65
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	127	$332.90
80365		<1%	179	$297.70
82465		<1%	70	$292.39
85130		<1%	25	$268.25
G0328	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous	<1%	13	$256.75
81250		<1%	12	$210.59
80356		<1%	179	$197.43
76098		<1%	79	$188.50
81255		<1%	12	$185.25
81290		<1%	12	$171.02
81251		<1%	12	$170.13
81200		<1%	12	$170.13
81330		<1%	12	$169.20
87184		<1%	27	$168.04
82272		<1%	41	$157.17
89051		<1%	27	$149.18
81260		<1%	12	$141.54
81209		<1%	12	$141.54
85660		<1%	26	$126.58
83010		<1%	13	$119.26
89060		<1%	13	$107.65
86886		<1%	14	$92.08
80051		<1%	13	$77.83
82340		<1%	13	$70.45
84075		<1%	12	$62.87

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCROSSEY, MICHAEL (CEO)